A patient in Blackburn or Bolton who has spent eighteen months on a waiting list for a specialist weight management referral will not care much that a tablet approved this week can be swallowed without the ritual of fasting water and empty stomachs that governs its rivals. Convenience is not what stands between most people in Britain and a GLP-1 prescription. Access is, and access has very little to do with pharmacology
The MHRA’s authorisation of orforglipron, sold as Foundayo, is being presented as a watershed moment, the drug that finally makes weight-loss medication scalable because it is a synthetic small molecule rather than a peptide that has to be manufactured under punishing biological constraints. That claim has real substance. The injectable shortages that plagued Wegovy and Mounjaro through 2024 and 2025 were partly a function of production complexity, and a tablet that skips that constraint genuinely changes what pharmaceutical companies can supply. What it does not change is what the NHS can absorb.
Consider where the system actually stands. NHS England’s own clinical director for diabetes and obesity told the Health and Social Care Committee earlier this summer that only around one per cent of eligible patients are currently accessing weight-loss treatment through the NHS. Mounjaro’s national rollout, agreed after NHS England warned NICE that a faster timetable would be “highly damaging” to wider GP access, was deliberately phased across as long as twelve years. That is not bureaucratic caution for its own sake. It reflects a primary care system that NHS England itself said lacked the weight management infrastructure to absorb a sudden surge of new patients without displacing everyone else waiting to see a GP.
Meanwhile the private market has filled the vacuum. An estimated two and a half million people in the UK are already taking GLP-1 drugs, and the overwhelming majority are paying for them outside the NHS, through pharmacies, online providers and private prescribers rather than general practice. A British Medical Journal investigation in January found that one in five local areas still had no functioning NHS pathway for Mounjaro at all. This is the postcode lottery that any assessment of Foundayo’s arrival has to reckon with. The drug does not enter a system with spare capacity waiting to deploy it. It enters a system already struggling to deliver the GLP-1 medicines it has approved.
Industry forecasts of seven million patients within a year deserve scrutiny rather than repetition. They describe a plausible ceiling for private and NHS uptake combined, not a projection of what NHS commissioning can fund or GP practices can staff. Because the affordability of addressing thousands of people with weight-related complications is not a calculation error in departmental budgets, NICE’s cost-effectiveness criteria has already forced NHS England to confront funding variations and longer rollout windows for its predecessors. Foundayo must pass a NICE health technology appraisal before it can reach a single NHS patient. Wes Streeting’s productivity and access pledges were not based on a medical speciality whose NHS track is already known to be underfunded, but rather on quantifiable gains in elective care and primary care contact.
What Foundayo genuinely offers is a manufacturing and distribution advantage that should, over time, ease supply pressure and lower unit costs as competition in the oral GLP-1 market increases. That is a meaningful development for life sciences policy and for NHS procurement leverage in future price negotiations. But it does nothing to resolve the workforce, training and commissioning constraints that determine whether a GP practice in a deprived ICB area can actually run a weight management pathway. Until those constraints are addressed, each new approval simply adds another product to a private market that increasingly serves as the NHS’s shadow delivery system, available to those who can pay and largely invisible to those who cannot.
